Loading
Testing 454 resected biliary cancers with the stomach cancer HER2 rules, nearly one in three gallbladder cancers was HER2-positive, far more than bile duct cancers inside the liver, but staining was patchy in most positive tumours.
HER2 protein expression by immunohistochemistry, HER2 gene amplification by fluorescence in situ hybridisation and both simultaneously by gene-protein assay were examined in 454 surgically resected biliary tract cancers: 110 intrahepatic cholangiocarcinomas, 67 perihilar and 119 distal extrahepatic cholangiocarcinomas, 80 gallbladder carcinomas and 79 ampullary carcinomas. HER2 status was assessed according to the guidelines for HER2 testing in gastro-oesophageal adenocarcinoma.
HER2-positive status was detected in 14.5% of biliary tract cancers: 3.7% of intrahepatic, 3.0% of perihilar and 18.5% of distal cholangiocarcinomas, 31.3% of gallbladder carcinomas and 16.4% of ampullary carcinomas. HER2 positivity tended to correlate with low histological grade. HER2 heterogeneity was common and highly frequent (83%) in positive cases, and reduced HER2 expression in the deeper invasive areas with simultaneous dedifferentiation was frequently observed.
The highest gallbladder HER2 rate in the literature comes from whole resected tumours scored generously; biopsy-based trial screening finds fewer. Heterogeneity is the practical warning for pathologists and for why HER2-directed drugs do not work in every positive tumour.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), Immunohistochemistry (IHC), HER2, Gallbladder cancer.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2 IHC 3+ (HER2-positive by immunohistochemistry), FISH / ISH (in situ hybridisation), Immunohistochemistry (IHC).
Shares National Cancer Center Hospital, HER2, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares HER2 testing in biliary tract cancer (IHC, ISH and NGS), HER2 IHC 3+ (HER2-positive by immunohistochemistry), FISH / ISH (in situ hybridisation), Immunohistochemistry (IHC).
Shares Ampullary cancer (ampulla of Vater), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Ampullary cancer (ampulla of Vater), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares HER2 IHC 3+ (HER2-positive by immunohistochemistry), HER2, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares National Cancer Center Hospital, HER2, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.